Lineage Cell Therapeutics Azioni (AMEX: LCTX)

Lineage Cell Therapeutics (AMEX:LCTX) Azioni

Lineage Cell Therapeutics

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics Inc

Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.15 by 8.7 percent. This is a 27.55 percent increase over earnings of $0.98 per share from the same period last year. The company reported quarterly sales of $829.00 million which missed the analyst consensus estimate of $831.34 million by 0.28 percent. This is a 5.74 percent increase over sales of $784.00 million the same period last year.

Earnings

News

Comerica Q1 2025 GAAP EPS $1.25 Beats $1.15 Estimate, Sales $829.00M Miss $831.34M Estimate

B. Riley Securities analyst Craig Ellis downgrades Axcelis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) from Buy to Neutral and lowers the price target from $80 to $50.

Downgrades

Price Target

Analyst Ratings

ACLS

B. Riley Securities Downgrades Axcelis Technologies to Neutral, Lowers Price Target to $50

On Thursday, April 17, U.S. markets closed mixed as investors balanced progress in trade talks with ongoing concerns about interest rates. Optimism followed positive comments on trade negotiations, but uncertainty remained about future deals. While some sectors saw gains, the broader market experienced declines over the week. Traders are focused on upcoming trade discussions and potential actions from the central bank.
In economic data, U.S. housing starts decreased by 11.4% month-over-month to an annualized rate of 1.324 million in March. Initial jobless claims fell by 9,000 to 215,000 in the second week of April, better than the expected 225,000. The Philadelphia Fed Manufacturing Index dropped by 39 points to -26.4 in April, well below the expected 2.
Most sectors on the S&amp;P 500 closed higher, led by energy, consumer staples, and real estate, while information technology and healthcare ended lower.
The Dow Jones Industrial Average declined 1.33% to 39,142.23, the S&amp;P 500 rose 0.13% to 5,282.70, and the Nasdaq Composite slid 0.13% to close at 16,286.45.
Asia Markets Today
<ul>
<li>On Monday, Japan&#8217;s Nikkei 225 fell 1.30% to close at 34,279.50, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.</li>
<li>Australian markets are closed for the Easter holiday.</li>
<li>India&#8217;s Nifty 50 was up 1.11% at 24,119.25, and Nifty 500 rose 1.45% to 21,994.95.</li>
<li>China&#8217;s Shanghai Composite rose 0.45% to 3,291.43, while Shanghai Shenzhen CSI 300 gained 0.33% to 3,784.88.</li>
<li>Hong Kong markets are closed for the Easter holiday.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>European markets closed for the Easter holiday.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 2.91% at $62.15/bbl, and Brent was down 2.80% at $66.05/bbl.</li>
<li>Oil prices dropped on Monday amid positive U.S.-Iran talks and concerns over an economic slowdown caused by tariffs. Lower liquidity and fears of reduced fuel demand heightened market volatility.</li>
<li>Natural Gas fell 0.96% to $3.216.</li>
<li>Gold was trading higher by 2.34% at $3,406.26, Silver was up 1.12% to $32.835, and Copper rose 0.87% to $4.7803.</li>
<li>Gold prices hit a new record on Monday, rising due to a weaker dollar, geopolitical tensions, and uncertainty surrounding U.S. Federal Reserve policy.        </li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.98%, S&amp;P 500 futures declined 1.12% and Nasdaq 100 futures fell 1.20%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index slipped 1.29% to 99.19, USD/JPY was down 1.07% to 140.65, and USD/AUD fell 0.18% to 1.5653.</li>
<li>The dollar fell sharply on Monday, hitting decade-lows against the Swiss franc and yen, as concerns grew over President Trump&#8217;s plans to challenge the independence of the Federal Reserve.</li>
</ul>
Photo by FOTOGRIN via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Gold Rallies To Record, Dollar Drops - Global Markets Today While US Slept

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) with a Buy and lowers the price target from $75 to $60.

CING

Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $60

Mizuho analyst Uy Ear initiates coverage on Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) with a Outperform rating and announces Price Target of $51.

Initiation

TECX

Mizuho Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $51

<ul>
<li>ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis</li>
<li>Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets</li>
<li>ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process</li>
<li>Special Meeting of Stockholders for both companies to be held May 13, 2025</li>
</ul>

ALMS

SLRN

Alumis And ACELYRIN Finalize Amended Merger Deal; New Terms Offer Greater Stake For ACELYRIN Shareholders

TORONTO, April 21, 2025 /CNW/ - Collective Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNL#NYSE">CNL</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNL#TSX">CNL</a>) ("Collective" or the "Company") is pleased to announce changes in the executive management of the Company effective immediately with the appointment of Ned Jalil as Chief Executive Officer, and former CEO Omar Ossma retaining his role as President and continuing to perform his same duties within the day-to-day operations of the Company.
 &nbsp;

Management

TSX:CNL

Collective Mining Names Ned Jalil CEO, Effective Immediately

Morgan Stanley analyst Benjamin Swinburne downgrades Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Overweight to Equal-Weight and lowers the price target from $37 to $32.

Morgan Stanley Downgrades Warner Music Gr to Equal-Weight, Lowers Price Target to $32

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the "Notice"), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule").
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until October 13, 2025, to regain compliance. If the Company fails to regain compliance with the Minimum Bid Price Rule during this period, the Company may consider applying to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market, provided that the Company meets the applicable market value of publicly held shares required for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market (except for the bid price requirement). Such transfer would provide the Company with an additional 180 calendar days, or until April 13, 2025, to regain compliance. There can be no assurance that the Company would be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company's request for continued listing.
The Notice has no immediate effect on the listing or trading of the Company's common shares.
The Company intends to monitor the bid price of its common shares and consider available options to regain compliance with the Minimum Bid Price Rule.

Government

Regulations

AFMD

Affimed Receives Nasdaq Notice Over Low Share Price, Has Until October to Regain Compliance

Chicago Fed President Austan Goolsbee has voiced serious concerns over President Donald Trump's recent remarks about removing Federal Reserve Chair Jerome Powell. What Happened: Trump's comments, made following <a href="https://fortune.com/2025/04/16/jerome-powell-tariffs-inflation-economy/">Powell's speech</a> at the Economic Club of Chicago, reignited a long-standing debate over the President's power to remove Federal Reserve leaders.
Goolsbee warned that such an action could severely undermine the credibility of the U.S. central bank, with far-reaching consequences for economic stability, as reported <a href="https://fortune.com/article/chicago-fed-president-austan-goolsbee-trump-terminate-jerome-powell-undermine-fed-credibility/">by</a> Fortune on Monday.
Trump has repeatedly criticized Powell for not cutting interest rates quickly enough in response to economic conditions, particularly following his controversial tariff policies.
Powell has argued that the tariff increases announced by Trump have significantly impacted inflation and economic growth, which led to his warnings.
Trump has blamed Powell for not acting swiftly enough to ease interest rates, which he believes are necessary to counter the negative economic effects of his policies.
See Also: <a href="https://benzinga.com/analyst-ratings/analyst-color/25/04/44883642/peter-schiff-rings-alarm-after-foreign-investors-dump-6-5-billion-in-us-equities-in" target="_blank" rel="noreferrer noopener">Peter Schiff Rings Alarm After Foreign Investors Dump $6.5 Billion In US Equities In A Week, Quips &#8216;Trump Thought Tariffs Would Bring Capital Into America&#8217;</a>
This conflict has drawn attention. Goolsbee, echoing the concerns of many economists, cautioned that removing Powell could set a dangerous precedent that could erode trust in the Fed.
"I strongly hope that we do not move ourselves into an environment where monetary independence is questioned," Goolsbee stated, highlighting the importance of keeping the Federal Reserve free from political influence.
Why It Matters: Trump&#8217;s criticism of Powell and his intention to terminate him have been a topic of concern for some time. Trump <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44861571/donald-trump-blasts-too-late-and-wrong-fed-chair-powell-but-polymarket-traders-doubt-his-termination-will-come-fast-enough">lashed out at Powell</a> for the Federal Reserve&#8217;s reluctance to cut interest rates.
This was followed by <a href="https://www.benzinga.com/markets/25/04/44883756/warren-foresees-market-turmoil-if-trump-dismisses-feds-powell-if-powell-can-be-fired-by-trump-it-will-crash-markets">Senator Elizabeth Warren&#8217;s warning</a> about a potential stock market collapse if Trump decides to fire Powell.
Investment strategists have also&nbsp;<a href="https://www.benzinga.com/news/25/04/44882256/trumps-threat-to-fire-powell-could-shake-us-financial-markets">warned</a>&nbsp;that Trump&#8217;s potential attempt to dismiss Powell could rattle U.S. financial markets and undermine central bank independence. Furthermore,&nbsp;<a href="https://www.benzinga.com/25/04/44888232/trumps-top-economic-adviser-kevin-hassett-says-white-house-is-exploring-options-to-fire-fed-chair-jerome-powell-the-president-and-his-team-will-continue-to-study">White House National Economic Council chair Kevin Hassett</a>&nbsp;confirmed that the Trump administration is exploring ways to remove Powell, adding to the uncertainty. Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://benzinga.com/25/04/44891314/dhl-says-its-suspending-global-shipments-to-us-valued-more-than-800-as-customs-updates-cause-multi-day-transit-de" target="_blank" rel="noreferrer noopener">DHL Says It&#8217;s Suspending Global Shipments To US Valued More Than $800 As Customs Updates Cause Multi-Day Transit Delays</a></li>
</ul>
Photo courtesy: Domenico Fornas / Shutterstock.com

Politics

Chicago Fed President Expresses Concern Over Trump's Intention To Dismiss Jerome Powell

Keefe, Bruyette &amp; Woods analyst David Konrad maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Market Perform and lowers the price target from $47 to $42.

FITB

Keefe, Bruyette & Woods Maintains Market Perform on Fifth Third Bancorp, Lowers Price Target to $42

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains First Finl Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIN#NASDAQ">FFIN</a>) with a Market Perform and lowers the price target from $38 to $36.

FFIN

Keefe, Bruyette & Woods Maintains Market Perform on First Finl Bankshares, Lowers Price Target to $36

Ascendiant Capital analyst Edward Woo maintains Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy and raises the price target from $19 to $20.

PSTV

Ascendiant Capital Maintains Buy on Plus Therapeutics, Raises Price Target to $20

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) with a Market Perform and lowers the price target from $75 to $73.

BANR

Keefe, Bruyette & Woods Maintains Market Perform on Banner, Lowers Price Target to $73

Keefe, Bruyette &amp; Woods analyst Kelly Motta upgrades F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) from Market Perform to Outperform and maintains the price target from $16.5 to $16.5.

Upgrades

Keefe, Bruyette & Woods Upgrades F N B to Outperform, Maintains Price Target to $16.5

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) with a Buy and raises the price target from $19 to $19.5.

PAVM

Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $19.5

Baird analyst Jonathan Komp upgrades Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) from Neutral to Outperform and maintains the price target from $15 to $15.

Baird Upgrades Wolverine World Wide to Outperform, Maintains Price Target to $15

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and raises the price target from $7 to $7.5.

LUCD

Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $7.5

Investar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISTR#NASDAQ">ISTR</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.43 by 48.84 percent. This is a 48.84 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $20.36 million which beat the analyst consensus estimate of $19.90 million by 2.29 percent. This is a 10.11 percent decrease over sales of $22.65 million the same period last year.

Comments

Lineage Cell Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO